Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

Accu-Chek FastClix Blood Lancing System

K-Number: K220608 · 2022-04-29

ApplicantRoche Diabetes Care, Inc.
Decision Date2022-04-29
Product CodeQRL
Advisory CommitteeSU
DecisionSubstantially Equivalent

Device Summary

Accu-Chek FastClix Blood Lancing System is a medical device manufactured by Roche Diabetes Care, Inc.. It received FDA 510(k) clearance on 2022-04-29 under approval number K220608. The device is classified under product code QRL. It was reviewed by the SU advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Accu-Chek FastClix Blood Lancing System?

Accu-Chek FastClix Blood Lancing System is a medical device that received FDA 510(k) clearance on 2022-04-29. It is manufactured by Roche Diabetes Care, Inc.. The 510(k) number is K220608.

When was Accu-Chek FastClix Blood Lancing System approved by the FDA?

Accu-Chek FastClix Blood Lancing System received FDA 510(k) clearance on 2022-04-29, under approval number K220608.

What company makes Accu-Chek FastClix Blood Lancing System?

Accu-Chek FastClix Blood Lancing System is manufactured by Roche Diabetes Care, Inc..

What is the FDA product code for Accu-Chek FastClix Blood Lancing System?

The FDA product code for Accu-Chek FastClix Blood Lancing System is QRL.

Related Clinical Trials

NCT01143558 Searching for Persistence of Infection in Lyme Disease COMPLETED NCT06727942 Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes RECRUITING NCT01143454 Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System RECRUITING NCT01174108 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells RECRUITING NCT07499128 Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event ENROLLING_BY_INVITATION NCT03331380 Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System RECRUITING

Related PubMed Literature

PMID: 41336744 From laboratory to pre-market prototyping: lessons learned from a noninvasive blood glucose level measurement device. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference (2025)

Other Devices by Roche Diabetes Care, Inc.

K160944ACCU-CHEK Guide Blood Glucose Monitoring System K220849Accu-Chek Safe-T-Pro Plus Lancing Device K203711IWL2020 Blood Glucose Monitoring System K220364Accu-Chek Safe-T-Pro Uno Lancing Device K214022Accu-Chek Softclix Blood Lancing System K232488Accu-Chek Safe-T-Pro Plus Lancing Device

View all 8 devices →

Related Devices (Code: QRL)

K222472Lancing System, Sterile Lancet for Single Use, Lancing DeviceShandong Lianfa Medical Plastic Products Co. , Ltd. K223099Facet Manatee Reusable Lancing BaseFacet Technologies, LLC K222656LDE4 Lancing DeviceI-Sens, Inc. K222246Disposable Sterile LancetTianjin Rilifine Medical Device Co., Ltd. K222539Facet Blood LancetsFacet Technologies, LLC K221072TRUEdraw Lancing Device, Mini Lancing DeviceTrividia Health

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑